Published in Vaccine Weekly, November 30th, 1998
The results are immensely encouraging for researchers pursuing AIDS vaccine strategies not based on a live, attenuated virus. Instead, the approach uses a live adenovirus (Ad-HIV) to deliver HIV antigens for priming and an HIV subunit vaccine for boosting.
Many HIV vaccine strategies are capable of protecting against challenge with the same HIV or SIV strain as those used in the vaccine preparations. A number of vaccine candidates have protected against heterologous challenge. But the current study is the first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly